JMPWA
DRUG

JP Morgan Private Wealth Advisors’s Bright Minds Biosciences DRUG Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,266
Closed -$14K – 1942
2022
Q3 		$14K Buy
+2,266
New +$14.7K ﹤0.01% 1912

Other funds holding DRUG

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
QFA
Quattro Financial Advisors The Woodlands, Texas $468M AUM 13.49% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

JP Morgan Private Wealth Advisors's DRUG Position: Q4 2022 in Review

JP Morgan Private Wealth Advisors sold out of Bright Minds Biosciences (DRUG) in Q4 2022, closing a stake of 2,266 shares — an estimated $14K sold.

JP Morgan Private Wealth Advisors first reported a position in DRUG in Q3 2022 and held it in 1 quarter. The position peaked at $14K in Q3 2022. 9 funds tracked by Wall St. Rank hold DRUG as of Q4 2022.

  • JP Morgan Private Wealth Advisors reported no remaining Bright Minds Biosciences position as of Q4 2022 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 2,266 Bright Minds Biosciences shares in Q4 2022, an estimated $14K.
  • JP Morgan Private Wealth Advisors first reported a position in Bright Minds Biosciences in Q3 2022 and held it in 1 quarter.
  • JP Morgan Private Wealth Advisors's Bright Minds Biosciences position peaked at $14K in Q3 2022.
  • 9 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q4 2022.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.